Language
English
Publication Date
1-1-2026
Journal
Frontiers in Immunology
DOI
10.3389/fimmu.2026.1853409
PMID
42292493
PMCID
PMC13260466
PubMedCentral® Posted Date
5-29-2026
PubMedCentral® Full Text Version
Post-print
Abstract
Background: Mesothelin (MSLN) is a GPI-anchored cell surface glycoprotein that is overexpressed in various solid tumors, including mesothelioma, triple-negative breast cancer, colon, ovarian and pancreatic cancer, with restricted normal tissue expression.
Methods: To explore the immunogenicity and immunotherapeutic potential of MSLN to T cells with native receptor specificity, 29 individuals of diverse HLA backgrounds were interrogated for T cell activity against MSLN.
Results: Twenty one (72%) subjects (21/29) mounted a specific T cell response when repetitively challenged with MSLN antigen. Reactive cells were Th1-polarized, polyfunctional, predominantly detected in the CD8+ T cell compartment and cytotoxic toward autologous and MSLN+/HLA-matched tumor cell lines in conventional 2D in vitro assays. Furthermore, these cells produced anti-tumor effects in a novel 3D tumor spheroid model system established to evaluate the potency of reactive cells against tumors including pancreatic, cervical, and colorectal cancer and mesothelioma.
Conclusions: These preclinical findings lay the groundwork for further exploration of MSLN as a potential immunotherapeutic target for T cells via the native T cell receptor.
Keywords
Humans, Mesothelin, GPI-Linked Proteins, Immunotherapy, Neoplasms, Female, Cell Line, Tumor, Antigens, Neoplasm, adoptive T cell immunotherapy of cancer, epitope identification, HLA diversity, HLA restriction, mesothelin, solid tumor, T cell receptor specificity, tumor-associated antigen
Published Open-Access
yes
Recommended Citation
Koukoulias, Kiriakos; Yanagisawa, Ryu; Torres Chavez, Alejandro G; et al., "Evaluating Mesothelin as an Immunotherapeutic Target for Endogenous T Cells" (2026). Faculty, Staff and Students Publications. 8114.
https://digitalcommons.library.tmc.edu/baylor_docs/8114